Drugs for Solid Tumors with Gene Alterations

Table. Drugs Prescribed for Solid Tumors with NTRK Gene Fusion

• Drug name (generic name)
• Drug company
• Indications
• Patient support services

Drug name (generic name)
• Jemperli (dostarlimab-gxly) Injection
Drug company
• GSK Oncology
Indications
• Treatment of adults with solid tumors associated with dMMR, as determined by an FDA-approved test, that have progressed during or after treatment and who have no satisfactory alternative treatment options
Patient support services
• Together with GSK Oncology Commercial Co-pay Program
  844-447-5662
  
  Jemperli Patient Assistance Program
  844-447-5662

Drug name (generic name)
• Keytruda (pembrolizumab)
Drug company
• Merck
Indications
• Treatment of adults and children with unresectable or metastatic, MSI-H or dMMR solid tumors that have progressed after previous treatment and who have no satisfactory alternative treatments
  
  Treatment of adults and children with unresectable or metastatic solid tumors and high tumor mutational burden, as determined by an FDA-approved test, that have progressed after previous treatment and who have no satisfactory alternative treatments
Patient support services
• Merck Co-pay Assistance Program
  855-257-3932
  
  Merck Patient Assistance Program
  855-257-3932

Drug name (generic name)
• Pedmark (sodium thiosulfate) Injection
Drug company
• Fennec Pharmaceuticals
Indications
• To reduce the risk of ototoxicity associated with cisplatin in pediatric patients aged 1 month-18 years with localized, nonmetastatic solid tumors
Patient support services
• Pedmark Copay Savings Program
  833-773-3627
  
  Patient Assistance Program
  833-773-3627
  
  Quick Start Program
  833-773-3627
  
  Bridge Program
  833-773-3627

Drug name (generic name)
• Retevmo (selpercatinib) Capsules
Drug company
• Eli Lilly
Indications
• Treatment of adult patients with locally advanced or metastatic solid tumors with RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options
Patient support services
• Retevmo Savings Card
  866-472-8663
  
  Lilly Cares Foundation Patient Assistance Program
  800-545-6962

Drug name (generic name)
• Rozlytrek (entrectinib) Capsules
Drug company
• Genentech
Indications
• Treatment of patients 12 or older with solid tumors and an NTRK gene fusion, are metastatic or are not candidates for surgery, or have progressed after treatment or they have no alternative therapy
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Tafinlar (dabrafenib) & Mekinist (trametinib)
Drug company
• Novartis
Indications
• Treatment of patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed after previous treatment and have no satisfactory alternative treatment options
Patient support services
• Novartis Oncology Universal Co-pay Program
  877-577-7756
  
  Novartis Patient Assistance Foundation
  800-277-2254

Drug name (generic name)
• Vitrakvi (larotrectinib) Capsules
Drug company
• Bayer
Indications
• Treatment of all patients with solid tumors and an NTRK gene fusion, are metastatic or are not candidates for surgery, or have no alternative treatments or have progressed after treatment
Genentech Oncology Co-pay Assistance Program
• VITRAKVI $0 Co-pay Program
  647-245-5637
  
  Bayer US Patient Assistance Foundation
  866-228-7723